Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at ...
Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC– Conference call on ...